Supreme Court Enforces US$2.06 Million Judgment Against Holista Colltech
Holista Colltech has agreed to pay US$1.8 million to settle a US judgment enforced by the Supreme Court of Western Australia, resolving a long-running dispute with ProImmune Company LLC. The settlement reflects a significant discount on the original US$2.06 million judgment plus accruing interest and legal fees.
- Supreme Court of Western Australia enforces US$2.06 million ProImmune judgment
- Holista’s defence and cross-claim rejected, summary judgment granted
- Settlement reached for US$1.8 million, including US$1 million initial payment
- Settlement amount is a discount on judgment plus post-judgment interest and fees
- Separate misleading conduct claim by Holista remains active
Australian Court Enforces US Judgment Against Holista
Holista Colltech Limited (ASX:HCT) has been hit with a summary judgment in favour of The ProImmune Company LLC, following a Supreme Court of Western Australia ruling that enforced a US court judgment of over US$2 million. The original judgment stemmed from a 2024 US District Court decision that found Holista breached minimum performance obligations under distribution agreements for its Immune Formulation 200® product.
The Australian court rejected Holista’s attempt to defend the enforcement via a cross-claim alleging misleading or deceptive conduct, ruling that the evidence was insufficient and that equitable set-off is not a valid defence against foreign judgment enforcement. This legal defeat in Australia follows the affirmation of the US judgment by the United States Court of Appeals in 2025.
Negotiated Settlement Cuts Holista’s Exposure
The settlement terms include an immediate payment of US$1 million, made on the day of the announcement, and a balance of US$800,000 due by mid-July 2026. Holista has already paid a US$500,000 deposit previously, which is incorporated into the settlement figure.
Ongoing Legal and Market Implications
While this settlement resolves the judgment debt and related claims, Holista’s separate claim alleging misleading or deceptive conduct remains unresolved, potentially leaving further legal uncertainty. The settlement follows a period where Holista’s shares were suspended due to the unresolved dispute with ProImmune, a situation that has clouded near-term trading and investor access.
The company’s decision to settle comes after months of legal wrangling and financial strain, including previous regulatory challenges such as a $1.09 million ASIC legal costs claim and efforts to stabilise cash flow amid market headwinds. The settlement reduces immediate financial risk but does not fully close the chapter on Holista’s legal challenges.
Holista’s ongoing efforts to navigate these headwinds while pursuing its core health and wellness business will be closely watched, especially given the company’s recent trading suspension amid unresolved legal dispute and the pressure to restore investor confidence.
Bottom Line?
Holista’s settlement cuts a significant financial risk but leaves open legal uncertainties that could affect its recovery trajectory.
Questions in the middle?
- How will the unresolved misleading conduct claim impact Holista’s future legal and financial position?
- What effect will the settlement and ongoing litigation have on Holista’s share suspension and investor confidence?
- Can Holista leverage its core health and wellness operations to offset legal and regulatory pressures?
